Drug intelligence / Profile preview

PVT501

Development stage: Preclinical
Lead developer: Parvus Therapeutics
Modality: Nanoparticles → Drug Delivery Systems, Peptides

Overview

PVT501 is a preclinical-stage peptide-MHC (pMHC) nanoparticle therapeutic developed by Parvus Therapeutics for the treatment of multiple sclerosis (MS). Utilizing the proprietary Navacim platform, PVT501 consists of disease-specific pMHC complexes conjugated to a nanoparticle core. The drug is designed to engage autoreactive T-cell receptors (TCRs) in an antigen-specific manner, triggering the expansion of regulatory T cells (Tregs) that suppress the autoimmune response associated with MS. This approach aims to restore immune tolerance without the broad immunosuppression typical of current MS treatments.

Targets

γδ TCR (T-cell receptor)

Beyond the preview

Go deeper on PVT501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PVT501.

Explore the full profile